BioLineRx (BLRX) Share-based Compensation (2014 - 2025)
BioLineRx's (BLRX) quarterly Share-based Compensation came in at $48000.0 in Q4 2025, up 131.17% year-on-year from $20764.0 in Q4 2024, and down 52.48% quarter-over-quarter from $101000.0 in Q3 2025.
BioLineRx (BLRX) Share-based Compensation (2014 - 2025) Analysis & Trends
BioLineRx's Share-based Compensation history runs 12 years deep, the most recent figure standing at $48000.0 for Q4 2025.
- On a quarterly basis, Share-based Compensation rose 131.17% year-over-year to $48000.0 in Q4 2025; TTM through Dec 2025 was $396000.0, a 65.11% decrease from a year earlier, with the FY2025 full-year figure at $396000.0, down 65.11% from the prior year.
- Share-based Compensation fell to $48000.0 in Q4 2025 per BLRX's latest filing, from $101000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.0 million in Q4 2022 and bottomed at -$154000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $376000.0 (2021), against an average of $379600.0.
- Across the five-year window, Share-based Compensation jumped 167.26% in 2022 and slumped 116.58% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $391000.0 in 2021, then soared by 167.26% to $1.0 million in 2022, then decreased by 11.1% to $929000.0 in 2023, then slumped by 116.58% to -$154000.0 in 2024, then soared by 131.17% to $48000.0 in 2025.
- Per Business Quant, the three latest BLRX Share-based Compensation figures stand at $48000.0 (Q4 2025), $101000.0 (Q3 2025), and $53000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | 48,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 48,000.00 |
| Dec 31, 2025 | 48,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Mar 31, 2025 | 194,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Sep 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Jun 30, 2024 | 437,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Mar 31, 2024 | 533,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Dec 31, 2023 | 929,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Sep 30, 2023 | 472,000.00 |